コンテンツへスキップ
Merck

C4397

クロルゾキサゾン

別名:

5-クロロ-2(3H)-ベンゾオキサゾロン, 5-クロロ-2-ヒドロキシベンゾキサゾール

ログインで組織・契約価格をご覧ください。

サイズを選択してください


この商品について

実験式(ヒル表記法):
C7H4ClNO2
CAS番号:
分子量:
169.57
NACRES:
NA.77
PubChem Substance ID:
UNSPSC Code:
12352200
EC Number:
202-403-9
MDL number:
テクニカルサービス
お困りのことがあれば、経験豊富なテクニカルサービスチームがお客様をサポートします。
お手伝いします
テクニカルサービス
お困りのことがあれば、経験豊富なテクニカルサービスチームがお客様をサポートします。
お手伝いします

InChI key

TZFWDZFKRBELIQ-UHFFFAOYSA-N

InChI

1S/C7H4ClNO2/c8-4-1-2-6-5(3-4)9-7(10)11-6/h1-3H,(H,9,10)

SMILES string

Clc1ccc2OC(=O)Nc2c1

assay

≥98% (TLC)

form

powder

color

white to off-white

mp

191-192 °C (lit.)

solubility

DMSO: 50 mg/mL, clear

originator

Johnson & Johnson

storage temp.

room temp

Quality Level

Gene Information

human ... KCNN4(3783)

類似した製品をお探しですか? 訪問 製品比較ガイド

関連するカテゴリー

Application

Chlorzoxazone may be used:
  • as a calcium-activated potassium (KCa) channel activator in patch-clamp electrophysiology to test its effect on dendritic hyperexcitability
  • as a substrate for cytochrome P450 2E1 (CYP2E1) enzyme in cultured human hepatocytes
  • as a benzimidazolone compound to test its effect on epithelial sodium (Na+) transport

Biochem/physiol Actions

Chlorzoxazone inhibits the multisynaptic reflex arcs primarily in the spinal cord and brain subcortical areas. It is an activator of calcium activated potassium channels and may contribute to the aortic artery relaxation in mice. Chlorzoxazone also activates the calcium-activated potassium (KCa) channel and small conductance calcium-activated potassium channels (SK). It is metabolized by cytochrome P450 2E1 (CYP2E1) and serves as a probe for monitoring this enzyme function.
Chlorzoxazone is a skeletal muscle relaxant.

Features and Benefits

This compound is a featured product for ADME Tox research. Click here to discover more featured ADME Tox products. Learn more about bioactive small molecules for other areas of research at sigma.com/discover-bsm.
This compound is featured on the Potassium Channels page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.
This compound was developed by Johnson & Johnson. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

pictograms

Exclamation mark

signalword

Warning

Hazard Classifications

Acute Tox. 4 Oral - Eye Irrit. 2 - Skin Irrit. 2 - STOT SE 3

target_organs

Respiratory system

保管分類

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

dust mask type N95 (US), Eyeshields, Gloves


適用法令

試験研究用途を考慮した関連法令を主に挙げております。化学物質以外については、一部の情報のみ提供しています。 製品を安全かつ合法的に使用することは、使用者の義務です。最新情報により修正される場合があります。WEBの反映には時間を要することがあるため、適宜SDSをご参照ください。

C4397-VAR: + C4397-BULK: + C4397-25G: + C4397-100G:

jan


最新バージョンのいずれかを選択してください:

試験成績書(COA)

Lot/Batch Number

適切なバージョンが見つかりませんか。

特定のバージョンが必要な場合は、ロット番号またはバッチ番号で特定の証明書を検索できます。

以前この製品を購入いただいたことがある場合

文書ライブラリで、最近購入した製品の文書を検索できます。

文書ライブラリにアクセスする

Karina Alviña et al.
The Journal of neuroscience : the official journal of the Society for Neuroscience, 30(21), 7258-7268 (2010-05-28)
Episodic ataxia type 2 (EA2) is a hereditary cerebellar ataxia associated with mutations in the P/Q-type voltage-gated calcium (Ca(2+)) channels. Therapeutic approaches for treatment of EA2 are very limited. Presently, the potassium (K(+)) channel blocker 4-aminopyridine (4-AP) constitutes the most
B J Powers et al.
Archives of internal medicine, 146(6), 1183-1186 (1986-06-01)
A drug rechallenge proved chlorzoxazone to be hepatotoxic in a patient who had been treated with a combination of it and acetaminophen (Parafon Forte) for several months. Failure to demonstrate a toxic response to acetaminophen coupled with a dramatic response
Sanjeev Kumar et al.
International journal of applied & basic medical research, 4(2), 101-105 (2014-08-22)
The fixed dose combinations (FDCs) of muscle relaxants, non-steroidal anti-inflammatory drugs and paracetamol are commonly prescribed in the treatment of acute lower backache. The present study was undertaken with the aim of comparing the efficacy and safety of FDCs of
C A Syme et al.
American journal of physiology. Cell physiology, 278(3), C570-C581 (2000-03-11)
We previously characterized 1-ethyl-2-benzimidazolinone (1-EBIO), as well as the clinically useful benzoxazoles, chlorzoxazone (CZ), and zoxazolamine (ZOX), as pharmacological activators of the intermediate-conductance Ca(2+)-activated K(+) channel, hIK1. The mechanism of activation of hIK1, as well as the highly homologous small-conductance
Karina Alviña et al.
The Journal of neuroscience : the official journal of the Society for Neuroscience, 30(21), 7249-7257 (2010-05-28)
Episodic ataxia type-2 (EA2) is an inherited movement disorder caused by mutations in the gene encoding the Ca(v)2.1alpha1 subunit of the P/Q-type voltage-gated calcium channel that result in an overall reduction in the P/Q-type calcium current. A consequence of these

資料

Discover Bioactive Small Molecules for ADME/Tox

ライフサイエンス、有機合成、材料科学、クロマトグラフィー、分析など、あらゆる分野の研究に経験のあるメンバーがおります。.

製品に関するお問い合わせはこちら(テクニカルサービス)